To mimic the daily clinical practice of radiographic assessment, we categorized the progression of joint damage in four categories: patients with no, dubious, moderate or high progression.
To use multiple imaging methods to investigate patients with type 2 idiopathic macular telangiectasia (IMT) at different disease severity stages so as to characterize and categorize disease progression through the full spectrum of disease phenotypes.
Subjects with poorer cardiovascular health could have died between the baseline assessment of AMD status and the follow-up visit to categorize AMD progression and cardiovascular health.
Extensive-stage small-cell lung cancer (SCLC) patients who progress after platinum-based chemotherapy are traditionally categorized as platinum sensitive (progression ≥ 90 days from last platinum dose) or refractory (progression < 90 days), a practice arising from seminal observations of worse survival in refractory patients.
Through analysis of baseline and repeat imaging data, patients were categorized as those with plaque progression or with no plaque progression.
There was a positive association between response (categorized as: NR, <VGPR; VGPR+CR) and progression after response assessment (P = 0.024; Fig. 2A).
By contrast, the rates of disease progression among those categorized to B*57-PD and those lacking a B*57 allele were not statistically different (Table 4, model 1), and this association remained after inclusion of the other covariates in the model (Table 4, models 2 to 10).
Patients were further categorized based on FIB-4 progression over the course of 5 years.
Compared to the classification based on equal difference of refraction progression, the cluster analysis categorized observations with similar patterns according to the characteristics of data.
EMT in cancer progression and metastasis is categorized as type 3 EMT.
The 2-year progression of CAC is categorized as follows: absent (≤25th percentile), moderate 25th-75thh percentiles), and accelerated (≥75th percentile).
